Literature DB >> 26869160

Comment on: 'Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab'.

D Călugăru1, M Călugăru1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26869160      PMCID： PMC4869140          DOI： 10.1038/eye.2016.2

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN： 0950-222X            Impact factor:   3.775


× No keyword cloud information.
  5 in total

1.  Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab.

Authors:  T D Papakostas; L Lim; T van Zyl; J B Miller; B S Modjtahedi; C M Andreoli; D Wu; L H Young; I K Kim; D G Vavvas; D D Esmaili; D Husain; D Eliott; L A Kim
Journal:  Eye (Lond)       Date:  2015-10-09       Impact factor: 3.775

2.  Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 GALILEO study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Am J Ophthalmol       Date:  2015-03       Impact factor: 5.258

3.  Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  J Ocul Pharmacol Ther       Date:  2014-10-14       Impact factor: 2.671

4.  Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.

Authors:  Peter A Campochiaro; David M Brown; Carl C Awh; S Young Lee; Sarah Gray; Namrata Saroj; Wendy Yee Murahashi; Roman G Rubio
Journal:  Ophthalmology       Date:  2011-06-29       Impact factor: 12.079

5.  Benefit from bevacizumab for macular edema in central retinal vein occlusion: twelve-month results of a prospective, randomized study.

Authors:  David L Epstein; Peep V Algvere; Gunvor von Wendt; Stefan Seregard; Anders Kvanta
Journal:  Ophthalmology       Date:  2012-08-17       Impact factor: 12.079
  5 in total
  3 in total

1.  Reply to 'Comment on: Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizmab'.

Authors:  T D Papakostas; D Vavvas; D Eliott; L A Kim
Journal:  Eye (Lond)       Date:  2016-02-12       Impact factor: 3.775

2.  Predictive factors for functional improvement following intravitreal bevacizumab injections after central retinal vein occlusion.

Authors:  Dan Călugăru; Mihai Călugăru
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2017-02-21       Impact factor: 3.117

Review 3.  Bevacizumab in the treatment of acute central/hemicentral retinal vein occlusions.

Authors:  Dan Călugăru; Mihai Călugăru; Ștefan Țălu
Journal:  Rom J Ophthalmol       Date:  2016 Jul-Sep
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.